164 related articles for article (PubMed ID: 36670396)
21. Non-suppressed thyrotropin and elevated thyroglobulin are independent predictors of recurrence in differentiated thyroid carcinoma.
Böhm J; Kosma VM; Eskelinen M; Hollmen S; Niskanen M; Tulla H; Alhava E; Niskanen L
Eur J Endocrinol; 1999 Nov; 141(5):460-7. PubMed ID: 10576761
[TBL] [Abstract][Full Text] [Related]
22. Serial Thyroglobulin Variation Trend Shortly after Radioiodine Therapy in Poorly to Moderately Differentiated Recurrent Thyroid Cancer.
Li CX; Hou M; Ren C; Lin YS
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2016 Jun; 38(3):351-5. PubMed ID: 27469925
[TBL] [Abstract][Full Text] [Related]
23. Early preablation rhTSH-stimulated thyroglobulin predicts outcome of differentiated thyroid cancer (DTC) patients.
Campennì A; Ruggeri RM; Siracusa M; Comis AD; Romano D; Vento A; Lanzafame H; Capoccetti F; Alibrandi A; Baldari S; Giovanella L
Eur J Nucl Med Mol Imaging; 2021 Jul; 48(8):2466-2475. PubMed ID: 33416957
[TBL] [Abstract][Full Text] [Related]
24. Stimulated thyroglobulin values above 5.6 ng/ml before radioactive iodine ablation treatment following levothyroxine withdrawal is associated with a 2.38-fold risk of relapse in Tg-ab negative subjects with differentiated thyroid cancer.
Mousa U; Yikilmaz AS; Nar A
Clin Transl Oncol; 2017 Aug; 19(8):1028-1034. PubMed ID: 28258491
[TBL] [Abstract][Full Text] [Related]
25. Blood thyroglobulin and TSH receptor mRNA detection by RT-PCR in the follow-up of differentiated thyroid cancer patients.
Torosian L; Manrique G; Alvarez B; Lago G; Roca R; Belzarena C
Rev Esp Med Nucl; 2010; 29(3):109-13. PubMed ID: 20399540
[TBL] [Abstract][Full Text] [Related]
26. Follow-up of differentiated thyroid carcinoma.
Pagano L; Klain M; Pulcrano M; Angellotti G; Pasano F; Salvatore M; Lombardi G; Biondi B
Minerva Endocrinol; 2004 Dec; 29(4):161-74. PubMed ID: 15765026
[TBL] [Abstract][Full Text] [Related]
27. Outcome of patients with differentiated thyroid cancer treated with empirical radioiodine therapy on the basis of Thyroglobulin Elevation Negative Iodine Scintigraphy (TENIS) syndrome without structural disease: a retrospective cohort study.
Yuan L; Wang J; Pan L; Feng H; Chen P; Luo J; Xie J; Xiong X; Wu J; Ouyang W
Ann Nucl Med; 2023 Jan; 37(1):18-25. PubMed ID: 36318362
[TBL] [Abstract][Full Text] [Related]
28. UNFAVORABLE RESPONSES TO RADIOIODINE THERAPY IN N1B PAPILLARY THYROID CANCER: A PROPENSITY SCORE MATCHING STUDY.
Liu YQ; Li H; Liu JR; Lin YS
Endocr Pract; 2019 Dec; 25(12):1286-1294. PubMed ID: 31412228
[No Abstract] [Full Text] [Related]
29. Correlation analysis of I-131 SPECT/CT uptake parameters with the success ablation treatment of thyroid remnant in patients with low-intermediate-risk differentiated thyroid cancer.
Zhang Q; Xu W
Nucl Med Commun; 2022 Oct; 43(10):1051-1057. PubMed ID: 35972341
[TBL] [Abstract][Full Text] [Related]
30. An enhanced treatment effect can be expected from a higher serum thyroglobulin level after radioactive iodine therapy.
Choi JH; Lim I; Lee I; Byun BH; Kim BI; Choi CW; Lim SM
Ann Nucl Med; 2019 Feb; 33(2):128-134. PubMed ID: 30382500
[TBL] [Abstract][Full Text] [Related]
31. Higher adjuvant radioactive iodine therapy dosage helps intermediate-risk papillary thyroid carcinoma patients achieve better therapeutic effect.
Li X; Zheng H; Ma C; Ji Y; Wang X; Sun D; Meng Z; Zheng W
Front Endocrinol (Lausanne); 2023; 14():1307325. PubMed ID: 38298190
[TBL] [Abstract][Full Text] [Related]
32. Recombinant human thyrotropin in follow-up of patients with differentiated thyroid cancer.
Podoba J
Bratisl Lek Listy; 2010; 111(1):38-40. PubMed ID: 20429310
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathologic risk factors of radioactive iodine therapy based on response assessment in patients with differentiated thyroid cancer: a multicenter retrospective cohort study.
Kwon SY; Lee SW; Kong EJ; Kim K; Kim BI; Kim J; Kim H; Park SH; Park J; Park HL; Oh SW; Won KS; Ryu YH; Yoon JK; Lee SJ; Lee JJ; Chong A; Jeong YJ; Jeong JH; Cho YS; Cho A; Cheon GJ; Choi EK; Hwang JP; Bae SK;
Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):561-571. PubMed ID: 31820047
[TBL] [Abstract][Full Text] [Related]
34. The Value of Stimulated Thyroglobulin Before the First Radioactive Iodine Treatment in Metastasis for Differentiated Thyroid Carcinoma.
Ren L; Zhang C; Shen Y; Mo A; Hu Y; Sun J; Yuan C; Wen W
Clin Lab; 2021 Jun; 67(6):. PubMed ID: 34107643
[TBL] [Abstract][Full Text] [Related]
35. Serum thyroglobulin concentrations and (131)I whole-body scan results in patients with differentiated thyroid carcinoma after administration of recombinant human thyroid-stimulating hormone.
David A; Blotta A; Bondanelli M; Rossi R; Roti E; Braverman LE; Busutti L; degli Uberti EC
J Nucl Med; 2001 Oct; 42(10):1470-5. PubMed ID: 11585859
[TBL] [Abstract][Full Text] [Related]
36. Serum thyroglobulin level after radioiodine therapy (Day 3) to predict successful ablation of thyroid remnant in postoperative thyroid cancer.
Kim YI; Im HJ; Paeng JC; Cheon GJ; Kang KW; Lee DS; Joon Park D; Park YJ; Chung JK
Ann Nucl Med; 2015 Feb; 29(2):184-9. PubMed ID: 25404419
[TBL] [Abstract][Full Text] [Related]
37. An evaluation of the value of first thyroglobulin determination in the diagnostics of metastases immediately following differentiated thyroid carcinoma surgery.
Makarewicz J; Adamczewski Z; Rutkowski A; Mikosiński S; Knapska-Kucharska M; Gonerska-Szadkowska A; Oszukowska L; Karwowska A; Lewiński A
Endokrynol Pol; 2006; 57(4):370-3. PubMed ID: 17006838
[TBL] [Abstract][Full Text] [Related]
38. Management of differentiated thyroid cancer with rising thyroglobulin and negative diagnostic radioiodine whole body scan.
Chao M
Clin Oncol (R Coll Radiol); 2010 Aug; 22(6):438-47. PubMed ID: 20561773
[TBL] [Abstract][Full Text] [Related]
39. Response to Therapy Assessment in Intermediate-Risk Thyroid Cancer Patients: Is Thyroglobulin Stimulation Required?
Moreno I; Hirsch D; Duskin-Bitan H; Dicker-Cohen T; Shimon I; Robenshtok E
Thyroid; 2020 Jun; 30(6):863-870. PubMed ID: 31928205
[No Abstract] [Full Text] [Related]
40. Low correlation between serum thyroglobulin and
Thai JN; De Marchena IR; Nehru VM; Landau E; Demissie S; Josemon R; Peti S; Brenner AI
Clin Imaging; 2022 Jul; 87():1-4. PubMed ID: 35439719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
